株式会社極東書店トップ商品一覧Adaptive Design Theory and Implementation Using SAS and R. 2nd edition

商品詳細

Adaptive Design Theory and Implementation Using SAS and R. 2nd edition

Adaptive Design Theory and Implementation Using SAS and R. 2nd edition

・ISBN 978-1-138-03423-5 paper GB£ 69.99

¥22,172.- (税込) (※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。

お気に入り
電子版あり 大学・学術機関向け電子ブック(eBook)ISBN 9780429174223
著者・編者Chang, Mark,
シリーズ (Chapman & Hall/CRC Biostatistics Series)
出版社 (CRC Press, UK)
出版年月2016
ページ数706 pp.
言語ENG
ニュース番号<A00-31611>

解説

Get Up to Speed on Many Types of Adaptive Designs

Since the publication of the first edition, there have been remarkable advances in the methodology and application of adaptive trials. Incorporating many of these new developments, Adaptive Design Theory and Implementation Using SAS and R, Second Edition offers a detailed framework to understand the use of various adaptive design methods in clinical trials.

New to the Second Edition

  • Twelve new chapters covering blinded and semi-blinded sample size reestimation design, pick-the-winners design, biomarker-informed adaptive design, Bayesian designs, adaptive multiregional trial design, SAS and R for group sequential design, and much more
  • More analytical methods for K-stage adaptive designs, multiple-endpoint adaptive design, survival modeling, and adaptive treatment switching
  • New material on sequential parallel designs with rerandomization and the skeleton approach in adaptive dose-escalation trials
  • Twenty new SAS macros and R functions
  • Enhanced end-of-chapter problems that give readers hands-on practice addressing issues encountered in designing real-life adaptive trials

Covering even more adaptive designs, this book provides biostatisticians, clinical scientists, and regulatory reviewers with up-to-date details on this innovative area in pharmaceutical research and development. Practitioners will be able to improve the efficiency of their trial design, thereby reducing the time and cost of drug development.